Alle Studien
Aktiv, aber nicht rekrutierendPHASE1INTERVENTIONELL

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

This research study is investigating a new treatment called [177Lu]Lu-DOTA-TATE for glioblastoma, an aggressive brain tumour. It's a 'dose-finding' study, meaning doctors are trying to find the best and safest amount to give. The study has two main groups: one for people newly diagnosed with glioblastoma, where the new treatment is given alongside standard treatments like radiotherapy and chemotherapy. The other group is for people whose glioblastoma has returned, and here the new treatment is given on its own. The main goal is to see if this new treatment is safe and to understand how it works in different situations.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE1
Sponsor
Novartis Pharma
Einschreibeziel
65
Starten
10 May 2022
Geschätzte Fertigstellung
31. Jul 2027

Worum geht es in dieser Studie?

This study is focused on a type of brain tumour called glioblastoma. This is a serious condition, and doctors are always looking for new and better ways to treat it. The new treatment being studied is called [177Lu]Lu-DOTA-TATE, which is a targeted therapy. This means it's designed to specifically find and treat cancer cells, hopefully causing less harm to healthy parts of the body.

The study is split into two main parts. For people who have been recently diagnosed with glioblastoma, the new treatment will be given along with their usual care – this typically includes radiotherapy and a chemotherapy drug called temozolomide. For people whose glioblastoma has come back (recurred), the new treatment will be given on its own. The primary aim is to figure out the best and safest dose of [177Lu]Lu-DOTA-TATE to use.

Before anyone starts treatment, a special scan will be done to see if their tumour has a specific feature called a 'somatostatin receptor'. This is important because the new treatment works by attaching to these receptors on cancer cells. The study will carefully follow participants for about a year to see how they respond and how they feel after treatment.

Wichtige Erkenntnisse

  • Tests a new treatment ([177Lu]Lu-DOTA-TATE) for glioblastoma.
  • Aims to find the safest dose of the new treatment.
  • Includes people newly diagnosed and those whose cancer has returned.
  • Involves regular scans and medical checks.
  • New treatment is given alongside standard care for newly diagnosed patients.
  • Follow-up lasts for 12 months after treatment.

Wer könnte berechtigt sein?

To join this study, you need to be at least 18 years old and have a confirmed diagnosis of glioblastoma. You'll also need to be generally well enough, with healthy blood counts and organ function. Before you can be considered for the study treatment, a special scan (PET/CT or PET/MRI) will be done to confirm that your tumour has a specific marker that the new treatment targets.

If you've been recently diagnosed, your tumour must show up on a special type of MRI scan, and you need to be able to do your usual daily activities fairly well. If your glioblastoma has come back (recurred), this must be your first or second time it has returned, and you must have already had standard treatments like radiotherapy. Again, your tumour needs to show up on a special MRI, and you generally need to be able to get around and do most things for yourself.

There are also reasons you might not be able to join. For example, you can't be receiving other active treatments for glioblastoma outside of the study, or have widespread cancer affecting the thin linings around your brain and spinal cord. If you've had another type of cancer in the last three years (unless it was completely treated), or have recently received other radioactive treatments, you might also not be eligible.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Do you have a confirmed diagnosis of glioblastoma?
  3. Are your blood counts and organ functions generally healthy?
  4. If newly diagnosed, is your tumour visible on a special MRI scan, and are you generally able to care for yourself?
  5. If your glioblastoma has come back, is this your first or second recurrence, and have you already had radiotherapy?
  6. Are you willing to have special scans to check for specific markers on your tumour?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, the study starts with a 'screening period' lasting up to six weeks. During this time, you'll have several checks, including a special scan called a PET scan to see if your tumour has the right 'targets' for the new treatment. Once confirmed, you'll start the 'treatment period'.

If you're newly diagnosed, you'll receive the study treatment called [177Lu]Lu-DOTA-TATE every four weeks, up to six times. A few days after your first dose, you'll also start your standard radiotherapy and chemotherapy (temozolomide) as usual. The radiotherapy involves daily sessions for about six weeks, and the chemotherapy will be taken by mouth. During your treatment, the dose of temozolomide might be adjusted based on how you're tolerating it. If your glioblastoma has come back, you'll receive the study treatment [177Lu]Lu-DOTA-TATE on its own, every three weeks.

Each time you get the [177Lu]Lu-DOTA-TATE treatment, you'll also receive a special amino acid mixture through a drip. This is given to protect your kidneys. After your treatment period, you'll be followed up for a full 12 months to see how you're doing and how the treatment has affected you.

Potenzielle Risiken und Vorteile

Taking part in a study like this could offer an opportunity to try a new treatment that isn't yet widely available, and it helps doctors learn more about glioblastoma. However, it's important to remember that this is a Phase 1 study, which means it's one of the first times this treatment is being directly tested in people. This means the main goal is to find a safe dose and understand its effects, and we don't yet know for sure if it will be effective. All treatments carry potential side effects, and some might be serious. The study team will explain these in detail. You are always free to decide to leave the study at any time, for any reason, without it affecting your usual medical care.

Standorte (14)

  • Col Uni Med Center New York Presby
    Verifizierte Postleitzahl
    New York, Vereinigte Staaten
  • University of Pittsburgh
    Verifizierte Postleitzahl
    Pittsburgh, United States
  • MD Anderson Cancer Center Uni of Te
    Verifizierte Postleitzahl
    Houston, Vereinigte Staaten
  • University of Wisconsin School of Medicine and Public Health
    Verifizierte Postleitzahl
    Madison, Vereinigte Staaten
  • Novartis Untersuchungsstelle
    Verifizierte Postleitzahl
    Bron, France
  • Novartis Untersuchungsstelle
    Verifizierte Postleitzahl
    Marseille, Frankreich
  • Novartis Untersuchungsstelle
    Verifizierte Postleitzahl
    Porto, Portugal
  • Novartis Untersuchungsstelle
    Verifizierte Postleitzahl
    Granada, Spain
  • Novartis Untersuchungsstelle
    Verifizierte Postleitzahl
    Barcelona, Spanien
  • Novartis Untersuchungsstelle
    Verifizierte Postleitzahl
    Barcelona, Spanien
  • Novartis Untersuchungsstelle
    Verifizierte Postleitzahl
    Madrid, Spanien
  • Novartis Untersuchungsstelle
    Verifizierte Postleitzahl
    Madrid, Spanien

Häufige Fragen

Was ist ein Glioblastom?

Glioblastoma is a serious and aggressive type of brain tumour that grows quickly.

What is [177Lu]Lu-DOTA-TATE?

It's a new targeted treatment being studied. It uses a radioactive substance to find and treat glioblastoma cells that have a specific marker.

What does 'dose-finding study' mean?

It means the study's main purpose is to find the safest and most effective amount (dose) of the new treatment to give.

Will I still get my usual treatment?

If you're newly diagnosed, yes, the new treatment will be given alongside your standard radiotherapy and chemotherapy. If your glioblastoma has recurred, you'll receive the study treatment on its own.

Wie lange werde ich an der Studie beteiligt sein?

You'll have a screening period, then a treatment period (duration depends on the group), followed by a 12-month follow-up period.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.